Lunasin potentiates the effect of oxaliplatin preventing outgrowth of colon cancer metastasis, binds to α 5β 1 integrin and suppresses FAK/ERK/NF-κB signaling

Cancer Letters

Volumn 313, Issue 2, 2011, Pages 167-180

  Dia, Vermont P ^a   Gonzalez de Mejia, Elvira ^a  

^a 228 ERML ^*  (United States)

Author keywords

Colon cancer; Integrin signaling; Lunasin; Metastasis; Soybean

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLINE; FOCAL ADHESION KINASE; I KAPPA B ALPHA; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUNASIN; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PROTEIN BAX; PROTEIN BCL 2; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER SIZE; CANCER TISSUE; CELL NUCLEUS; CELL STRAIN HCT116; CELL STRAIN KM12L4; CELL STRAIN RKO; COLON CANCER; COLORECTAL CANCER; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIVER METASTASIS; LIVER NODULE; MALE; METASTASIS INHIBITION; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FOCAL ADHESION KINASE 1; HUMANS; I-KAPPA B KINASE; INTEGRIN ALPHA5BETA1; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; ORGANOPLATINUM COMPOUNDS; PROLIFERATING CELL NUCLEAR ANTIGEN; SIGNAL TRANSDUCTION; SOYBEAN PROTEINS;

GLYCINE MAX;

EID: 82655173826     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.09.002     Document Type: Article

References (51)

1. Galvez A.F., Chen N., Macasieb J., de Lumen B.O. Chemopreventive property of a soybean peptide (lunasin) that binds to deacetylated histones and inhibits acetylation. Cancer Res. 2001, 61:7473-7478.
2. Dia V.P., Wang W., Oh V.L., de Lumen B.O., Gonzalez de Mejia E. Isolation, purification and characterization of lunasin from defatted soybean flour and in vitro evaluation of its anti-inflammatory activity. Food Chem. 2009, 114:108-115.
3. Gonzalez de Mejia E., Dia V.P. Lunasin and lunasin-like peptides inhibit inflammation through suppression of NF-κB pathway in the macrophage. Peptides 2009, 30:2388-2398.
4. Hernandez-Ledesma B., Hsieh C., de Lumen B.O. Anti-oxidant and anti-inflammatory properties of cancer preventive peptide lunasin in RAW 264.7 Macrophages. Biochem. Biophys. Res. Commun. 2009, 390:803-808.
5. Liu C.F., Pan T.M. Recombinant expression of bioactive peptide lunasin in Escherichia coli. Appl. Microbiol. Biotechnol. 2010, 88:177-186.
6. Gonzalez de Mejia E., Wang W., Dia V.P. Lunasin, with an arginine-glycine-aspartic acid motif, causes apoptosis to L1210 leukemia cells by activation of caspase-3. Mol. Nutr. Food Res. 2010, 54:406-414.
7. Dia V.P., Gonzalez de Mejia E. Lunasin promotes apoptosis in human colon cancer cells by mitochondrial pathway activation and induction of nuclear clusterin expression. Cancer Lett. 2010, 295:44-53.
8. Dia V.P., Gonzalez de Mejia E. Lunasin induces apoptosis and modifies the expression of genes associated with extracellular matrix and cell adhesion in human metastatic colon cancer cells. Mol. Nutr. Food Res. 2011, 55:623-634.
9. de Mejia E.G., Dia V.P. The role of nutraceutical proteins and peptides in apoptosis, angiogenesis, and metastasis of cancer cells. Cancer Metastasis Rev. 2010, 29:511-528.
10. Dittmar T., Heyder C., Gloria-Maercker E., Hatzmann W., Zanker K.S. Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner. Clin. Exp. Metastasis 2008, 25:11-32.
11. Paolillo M., Russo Serra M.A., Colombo L., Schinelli S S. Small molecules integrin antagonists for cancer therapy. Mini-Rev. Med. Chem. 2009, 9:1439-1446.
12. Mitra S.K., Schlaepfer D.K. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell Biol. 2006, 18:516-523.
13. Gentilucci L., Cardillo G., Spampinato S., Tolomelli A., Squassabia F., De Marco R., Bedini A., Bauila M., Belvisi L., Civera M. Antiangiogenic effect of dual/selective alpha 5 beta 1/alpha v beta 3 integrin antagonists designed on partially modified reto-inversocyclotetrapeptidemimetic. J. Med. Chem. 2010, 53:106-118.
14. Avraamides C.J., Garrny-Susini B., Varner J.A. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 2008, 8:604-617.
15. Parsons-Wingerter P., Kasman I.M., Norberg S., Magnussen A., Zanivan S., Rissone A., Baluk P., Favre C.J., Jeffry U., Murray R., McDonald D.M. Uniform overexpression and rapid accessibility of alpha 5 beta 1 integrin on blood vessels in tumors. Am. J. Pathol. 2005, 167:193-211.
16. Kim S., Harris M., Varner M.J.A. Regulation of integrin alpha v beta 3-mediated endothelial cell migration and angiogenesis by integrin alpha 5 beta 1 and protein kinase A. J. Biol. Chem. 2000, 275:33920-33928.
17. Bewick M.A., Lafrenie R.M. Adhesion dependent signaling in the tumour microenvironment: the future drug targeting. Curr. Pharm. Des. 2006, 12:2833-2848.
18. Jemal A., Freddie B., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
19. Markle B., May E.J., Majumdar A.P.N. Do nutraceutics play a role in the prevention and treatment of colorectal cancer?. Cancer Metastasis Rev. 2010, 29:395-404.
20. Gupta G.P., Massague J. Cancer metastasis: building a framework. Cell 2006, 127:679-695.
21. van Iersel L.B.J., Koudjis T.M., Hoekkam E.J., Janssen-van Rhijn C.M., Vahrmeijer A.L., Nortier J.W.R., van de Velde C.J.H., Gelderblom H., Kuppen P.J.K. In vitro scheduled-dependent interaction between melphalan and oxaliplatin in human colorectal cancer cell lines. J. Surg. Res. 2011, 167:273-278.
22. Extra J.M., Marty M., Brienza S., Misset J.L. Pharmacokinetics and safety profile of oxaliplatin. Semin. Oncol. 1998, 25:S5. 13-22.
23. Raymond E., Chaney S.G., Taamma A., Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann. Oncol. 1998, 9:1053-1071.
24. Rotheberg M.L., Oza A.M., Bigelow R.H., Berlin J.D., Marshall J.L., Ramanathan R.K., Hart L.L., Gupta S., Garay C.A., Burger B.G., Le Bail N., Haller D.G. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J. Clin. Oncol. 2003, 21:2059-2069.
25. Ramanathan R.K., Clark J.W., Kemeny N.E., Lenz H.J., Gococo K.O., Haller D.G., Mitchell E.P., Kardinal C.G. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J. Clin. Oncol. 2003, 21:2904-2911.
26. Morikawa K., Walker S.M., Nakajima M., Pathak S., Jessup J.M., Fidler I.J. Influence of organ environment on the growth, selection and metastasis of human colon carcinoma cells in nude mice. Cancer Res. 1988, 48:6863-6871.
27. De Luca L.M., Adamo S., Kato S. Retinoids and the control of adhesion. Methods Enzymol. 1990, 190:81-89.
28. Van Buren G., Gray M.J., Dallas N.A., Xia L., Lim S.J., Fan F., Mazar A.P., Ellis L.M. Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver. Cancer 2009, 115:3360-3368.
29. Hsieh C.C., Hernandez-Ledesma B., Jeong H.J., Park J.H., de Lumen B.O. Complementary roles in cancer prevention: protease inhibitor makes the cancer preventive peptide lunasin bioavailable. PLoS ONE 2010, 5. Article number e8890.
30. Maldonado-Cervantes E., Jeong H.J., Leon-Galvan F., Barrera-Pacheco A., de Leon-Rodriguez A., de Mejia E.G., de Lumen BO B.O., de la Rosa A.P.B. Amaranth lunasin-like peptide internalizes into the cell nucleus and inhibits chemical-induced transformation of NIH-3T3 cells. Peptides 2010, 31:1635-1642.
31. Hsieh C.C., Hernandez-Ledesma B., de Lumen B.O. Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem. - Biol. Interact. 2010, 186:127-134.
32. Hsieh C.C., Hernandez-Ledesma B., de Lumen B.O. Soybean peptide lunasin suppresses in vitro and in vivo 7,12-dimethylbenz-[a]anthracene-induced tumorigenesis. J. Food Sci. 2010, 75:H311-H316.
33. Conconi M.T., Ghezzo F., Dettin M., Urbani L., Grandi C., Guidolin D., Nico B., Di Bello C., Ribatti D., Parnigotto P.P. Effects on in vitro and in vivo angiogenesis induced by small peptides carrying adhesion sequences. J. Pept. Sci. 2010, 16:349-357.
34. Frisch S.M., Screaton R.K. Anoikis mechanisms. Curr. Opin. Cell Biol. 2011, 13:555-562.
35. Ruoslahti E., Pierschbacher M.D. New perspectives in cell adhesion - RGD and integrins. Science 1987, 238:491-497.
36. Pierchbacher M.D., Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984, 309:30-33.
37. Danen E.H.J., Yamada K.M. Fibronectin, integrins and growth control. J. Cell. Physiol. 2001, 189:1-13.
38. Yang A.D., Fan F., Ramsay Camp E., van Buren G., Liu W., Somcio R., Gray M.J., Cheng H., Hoff P.M., Ellis LM L.M. Chronic oxaliplatin resistance induces epithelial-tomesenchymal transition in colorectal cancer cell lines. Clin. Cancer Res. 2006, 12:4147-4153.
39. Jani T.S., DeVecchio J., Mazumdar T., Agyeman A., Houghton J.A. Inhibition of NF-κB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J. Biol. Chem. 2010, 285:19162-19172.
40. Ban J.O., Kwak D.H., Oh J.H., Park E.J., Cho M.S., Song H.S., Song M.J., Han S.B., Moon D.C., Kang K.W., Hong J.T. Suppression of NF-κB and GSK-3β is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chem. - Biol. Interact. 2010, 188:75-85.
41. Tan T.W., Lai C.H., Huang C.Y., Yang W.H., Chen H.T., Hsu H.C., Fong Y.C., Tang C.H. CTGF enhances migration and MMP-13 up-regulation via alpha v beta 3 integrin, FAK, ERK, and NF-kappa B-dependent pathway in human chondrosarcoma cells. J. Cell. Biochem. 2009, 107:345-356.
42. Enns A., Korb T., Schluter K., Gassman P., Spiegel H.J., Senninger N., Mitjans F., Haler J. Alpha v beta 5-integrins mediate early steps of metastasis formation. Eur. J. Cancer 2005, 41:1065-1072.
43. Haier J., Goldmann U., Hotz B., Runkel N., Keilholz U. Inhibition of tumor progression and neoangiogenesis using cyclic RGD-peptides in a chemically induced colon carcinoma in rats. Clin. Exp. Metastasis 2002, 19:665-672.
44. Kawaguchi M., Hosotani R., Ohishi S., Fujii N., Tulachan S.S., Koizumi M., Toyoda E., Masui T., Nakajima S., Tsuji S., Ida J., Fujimoto K., Wada M., Doi R., Imamura M. A novel synthetic arg-gly-asp-containing peptide cyclo(-RGDf=V-) is the potent inhibitor of angiogenesis. Biochem. Biophys. Res. Commun. 2001, 288:711-717.
45. Rosenow F., Ossig R., Thormeyer D., Gasmann P., Schluter K., Brunner G., Haier J., EblE J.A. Integrins as antimetastatic targets of RGD-independent snake venom components in liver metastasis. Neoplasia 2008, 10:168-176.
46. Bogenrieder T., Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 2003, 22:6524-6536.
47. Fidler I.J. The pathogenesis of cancer metastasis: the " seed" and " soil" hypothesis revisited. Nat. Rev. Cancer 2003, 3:1-6.
48. Nicolson Cancer G.L. Metastasis: tumor cell and host properties important in colonization of specific secondary sites. Biochim. Biophys. Acta 1988, 948:175-224.
49. Enns A., Korb T., Schluter K., Gassmann P., Spiegel H.U., Senninger N., Mitjans F., Haier J. αvβ5-integrisn mediate early steps of metastasis formation. Eur. J. Cancer 2005, 41:1065-1072.
50. Wilsom P.M., LaBonte M.J., Lenz HJ H.J. Molecular markers in the treatment of metastatic colorectal cancer. Cancer J. 2010, 16:262-272.
51. Martinez-Hernandez A., Amenta P.S. The hepatic extracellular matrix. I. Components and distribution in normal liver. Virchows Arch. A Pathol. Anatomy Histopathol. 1993, 423:1-11.